Search

Displaying results 2211 - 2220 of 7540 in total
  1. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000
  2. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28]. … It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.

  3. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    It is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  4. Drug

    Natamycin

    go.drugbank.com/drugs/DB00826
    ApprovedInvestigational

    Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]

    International brands: N-Mycin
  5. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862] … [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  6. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other

  7. Drug

    Flavin adenine dinucleotide

    go.drugbank.com/drugs/DB03147
    Approved

    A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinuc...

  8. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  9. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines

  10. Drug

    Enoximone

    go.drugbank.com/drugs/DB04880
    ApprovedInvestigationalWithdrawn

    Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.